Evaluation of S-T Resolution by Streptokinase Therapy in Patients of Myocardial Infarction among the Age Group of more than 60 Years
Keywords:
Streptokinase, ECG, ST-elevation, Myocardial infarction, EfficacyAbstract
Objective: To evaluate the benefit and efficacy of streptokinase therapy on ST-segment elevation resolution in different types
of myocardial infarction in more than 60 years age group.
Materials and Methods:This Hospital based cross sectional study was conducted at National Institute of Cardiovascular
Diseases (NICVD) of Karachi, Pakistan. The study included patients more than 60 years of age having different types of
myocardial infarction. Fifty patients both male & female fulfilling the inclusion criteria for thrombolytic therapy were included.
Baseline ECG was recorded before streptokinase infusion and repeated at completion of infusion, at 90 minutes, day 1 and day
2. Effect of streptokinase therapy (SK) on blood pressure, CKMB, and ST-segment resolution was also evaluated at 90 minutes,
day 1, and Day 2.
Results: The mean systolic blood pressure was 138.20±4.57 and 125.20±3.92 pre and post SK therapy reflecting a percentage
decrease of 9.40 and highly significant (P<0.001). The Diastolic blood pressure was decrease to 9.52% with a mean value of
84.80± 2.46 and 76.80±1.89 before and after the Streptokinase therapy’s, segment resolution at 90 minutes was decreased to
50.69 percent from the baseline and continued to decrease at Day-1 and Day-2 with a percentage reduction of 69.12 and 84.33
% respectively. The P values were highly significant (P<0.001).
Conclusion: Thrombolysis when given within 12 hours of the onset of symptoms, improves survival, is beneficial and
effective.The magnitude of benefit is greatest when reperfusion is established early. Age itself should not be considered a
contraindication for fibrinolysis.
References
Véronique L Roger. Epidemiology of myocardial infar- ction. Med Clin North Am 2007; 91(4):537-9
Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994; 343:311- 22
Ohman, EM, Harrington, RA, Cannon, CP Intravenous thrombolysis in acute myocardial infarction. Chest 2001;119, 253S-77S
Qureshi,AE, Jafri NA, Noeman A, Yasmin S, Khalil H. Streptokinase for acute myocardial infarction in the el- derly. J Ayub Med Coll Abbottabad. 2014;26(4):535-8
BrogdenRN, SpeightTM, Avery GS. Streptokinase: a review of its clinical pharmacology, mechanism of action and therapeutic uses. Drugs 1973;5(5):357-445
McNel JJ, Krum H. Cardiovascular Disorders In Avery's Drug Treatment Eds Speight TM, Halford NHG AdisInte- rnational Auckland 1997;809-96
FusterV, BadimonL,Badimon J, ChesebroJH. The pathog- enesis of coronary artery disease and acute coronary syndromes. N.Engl.J.Med 1992; 326:242-50
Shah PK ,Forrester JS. Pathophysiology of acute coronary syndrome. Am J Cardiol 1991; 68(Suppl 6):16C-23C
Falk E,Fernendez A. Role of thrombosis in atherosclerosis and its complications. Am.J.Cardiol 1995; 75:5B-11B
Davies MJ, Thomas AC. Plaque fissuring, the cause of acute myocardial infarction, sudden ischemic death and crescendo angina. Br.Heart.J 1985; 53:363-73
TIMI III-B investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conser- vative strategies in unstable angina and non-Q wave’s myocardial infarction: Results of TIMI III B trials. Circu- lation 1994; 89:1545-56
Cannon CP. Defining acute myocardial infarction by ST -segment elevation.
Euro.Heart.J.2000; 21:266-7
Collin D, Lijnin HR. Basic and clinical aspects of fibrin- olysis. Blood 1991; 78(12):3114-24
The time investigator. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary artery diseases. (TIME): a randomized trial. Lancet 2001; 358: 951-7
Jerry H.G, Joel MG, Rebost JG, Michael R ,Nisha C, William JR. Recent age related trends in the use of thr- ombolytic therapy in patients who have had acute myo- cardial infarction. Lancet 1985; 326 (8455):578-81
Laurie A O, Aufderheide TP. Evaluation of ST-segment elevation criteria for the pre-hospital electrocardiographic diagnosis of acute myocardial infarction. Circulation 1993;70: 606-18
GISSI. Effectiveness of intra-venous thrombolytic treat- ment in acute myocardial infarction. Lancet 1986; 1:397- 402
Schruder R, Biamino G, Enz-Rudiger v, LindererT. Int- ravenous short term infusion of streptokinase in acute myocardial infarction. Circulation 1983; 67(3):536-48
FTT collaborative group: Indication of fibrinolytic ther- apy in suspected myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343(8893):311-22
Brügemann J, de Graeff PA, van der Meer J, Lie KI. Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients? Drugs Aging. 1995 Aug;7(2):110-6
Krumholz HM, Pasternak RC, Weinstein MC, Friesinger GC, Ridker PM, Tosteson AN et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med. 1992; 327(1):7-13
Ross AM.Thrombolytic therapy for acute myocardial infarction. CardiovascClin. 1989; 20(1): 209-18
Franken M, Nussbacher A, Liberman A, Wajngarten M. ST Elevation Myocardial Infarction in the elderly. J Ger- iatrCardiol 2012;9(2):108-14
O'Gara PT, Kushner FG, Ascheim DD. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Ass- ociation Task Force on Practice Guidelines. Circulation 2013; 127:529
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Shaikh Nadeem Ahmad, Fuad Shiekh, Musarrat Sultana, Syed Saud Hasan, Shams-ul-Arfeen Qasmi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0